Validation of a Machine Learning Diagnostic Tool for the Prediction of Sepsis and Critical Illness

Akhil Bhargava, M.S.¹; Carlos Lopez-Espina, M.S.¹; Lee Schmalz, B.S.¹; Shah Khan, PhD,¹; Gregory L. Watson, PhD,¹; Dennys Urdiales B.S.¹; Lincoln Updike B.S.¹; Niko Kurtzman, M.D.²; Alon Dagan, M.D.³; Amanda Doodlesack, M.D.³; Bryan Stenson, M.D.³; Deesha Sarma, M.D.³; Eric Reseland, M.D.³; John H. Lee, M.D. PhD³; Max Kravitz, M.D.³, Peter S. Antkowiak, M.D., MPH³; Tatyana Shvilkina, D.O.³; Aimee Espinosa, M.D.⁵; Alexandra Halalau, M.D.⁵; Carmen Demarco, M.D.⁵; Francisco Davila, M.D.⁵; Hugo Davila, M.D.⁵; Matthew Sims, M.D., Ph.D.⁵; Nicholas Maddens, M.D.⁵; Ramona Berghea, M.D.⁵; Scott Smith, M.D.⁵; Ashok V. Palagiri, M.D.⁶; Clinton Ezekiel, M.D.⁶; Farid Sadaka, M.D.⁶; Karthik Iyer, M.D.⁶; Matthew Crisp, M.D., Ph.D.⁶; Saleem Azad, D.O.⁶; Vikram Oke, M.D.⁶; Andrew Friederich, M.D.⁶; Anwaruddin Syed, M.D.⁶; Falgun Gosai, M.D.⁶; Lavneet Chawla, M.D.⁶; Neil Evans, M.D.⁶; Kurian Thomas, M.D.¹⁰; Roneil Malkani, M.D.¹⁰; Roshni Patel, M.D.¹⁰; Stockton Mayer, D.O.¹⁰ Farhan Ali, M.D.¹¹; Lekshminarayan Raghavakurup, M.D.¹¹; Muleta Tafa, M.D., MPH¹¹; Sahib Singh, M.D.¹¹; Samuel Raouf, M.D.¹¹; Sihai Dave Zhao, PhD¹²; Ruoqing Zhu PhD,¹²; Rashid Bashir, PhD¹³; Bobby Reddy, Jr. PhD¹ and Nathan I. Shapiro M.D., MPH¹¹,3,4

Corresponding author:
Nathan I. Shapiro, MD, MPH
Professor of Emergency Medicine
Department of Emergency Medicine
Beth Israel Deaconess Medical Center
Boston, MA
Nshapiro@bidmc.harvard.edu

Word Count: 2886

<sup>&</sup>lt;sup>1</sup> Prenosis, Inc., Chicago, Illinois, United States

<sup>&</sup>lt;sup>2</sup> Emory School of Medicine, Atlanta, Georgia, United States

<sup>&</sup>lt;sup>3</sup> Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

<sup>&</sup>lt;sup>4</sup> Harvard Medical School, Boston, Massachusetts, United States

<sup>&</sup>lt;sup>5</sup> Beaumont Health System, Royal Oak, Michigan, United States

<sup>&</sup>lt;sup>6</sup> Mercy Hospital, St. Louis, Missouri, United States

<sup>&</sup>lt;sup>7</sup> Mercy Hospital, Jefferson, Missouri, United States

<sup>&</sup>lt;sup>8</sup> OSF Saint Francis Medical Center, Peoria, Illinois, United States

<sup>&</sup>lt;sup>9</sup> Davis School of Medicine, University of California, Sacramento, California, United States

Jesse Brown VA Medical Center, Chicago, Illinois, United States

<sup>11</sup> Lifebridge Sinai Hospital, Baltimore, Maryland, United States

<sup>&</sup>lt;sup>12</sup> Department of Statistics, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States

<sup>&</sup>lt;sup>13</sup> Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States

**Key Points** 

Question: Is it feasible to develop an Artificial Intelligence/Machine Learning (AI/ML) learning model

that accurately identifies patient risk for sepsis and sepsis-related critical illness?

Findings: The FDA approved AI/ML Sepsis ImmunoScore algorithm was created using a

combination of 22 different demographic, clinical, and laboratory variables to predict risk of sepsis

within 24 hours. The model was accurate, with an AUROC of 0.81 (0.77-0.86) in external

validation. The algorithm was also predictive of secondary outcomes of sepsis-related critical

illness.

Meaning: This Sepsis ImmunoScore algorithm identifies patients suspected of infection who are at

high risk of having or developing sepsis and sepsis-related critical illness.

**Abstract** 

Importance: Prompt and accurate diagnosis and risk assessment is a challenge with

implications for clinical care of sepsis patients.

Objective: To describe the development of the Sepsis ImmunoScore Artificial

Intelligence/Machine Learning (AI/ML) algorithm and assess its ability to identify patients with

sepsis within 24 hours, and secondary endpoints of critical illness and mortality.

Design: Prospective study of adult (age 18 or older) patients from 5 US hospitals enrolled

between April 2017 and July 2022.

**Setting:** Multi-center study from 5 hospitals

Participants: Inclusion criteria: suspected infection (indicated a blood culture order).

emergency department or hospitalized patients, with a corresponding lithium-heparin plasma

sample available; exclusion criteria: none. Participants were enrolled into an algorithm development derivation cohort (n=2,366), an internal validation (n=393) cohort, or an external validation cohort (n=698).

Main Outcomes and Measures: The primary endpoint was the presence of sepsis (Sepsis-3) within 24 hours of test initiation. Secondary endpoints were clinically relevant metrics of critical illness: length of stay in the hospital, Intensive Care Unit (ICU) admission within 24 hours, use of mechanical ventilation within 24 hours, use of vasopressors within 24 hours, and in-hospital mortality.

**Results:** The overall diagnostic accuracy of the Sepsis ImmunoScore for predicting sepsis was high with an AUC of 0.85 (0.83–0.87) in the derivation cohort, 0.80 (0.74–0.86) in internal validation, and 0.81 (0.77–0.86) in external validation. The Sepsis ImmunoScore was divided into four risk categories with increasing likelihood ratios for sepsis: low 0.1 (0.1–0.2), medium 0.5 (0.3–0.8), high 2.1 (1.8–2.5), very high 8.3 (4.1–17.1). Risk categories also predicted inhospital mortality rates: low: 0.0% (0.0%, 1.6%), medium: 1.9% (0.4%–5.5%), high: 8.7% (5.7%–12.7%), and very high: 18.2% (7.0%–35.5%) in the external validation cohort. Similar findings were observed for length of stay, ICU utilization, mechanical ventilation and vasopressor use.

Conclusions and Relevance The sepsis ImmunoScore, an AI/ML diagnostic tool, demonstrated high accuracy for predicting sepsis and critical illness that could enable prompt identification of patients at high risk of sepsis and adverse outcomes, which holds promise to inform medical decision making to improve care and outcomes in sepsis.

## Introduction

Sepsis is a serious medical condition caused by a dysregulated immune response to infection, which can lead to organ dysfunction and significant morbidity and mortality. Early treatment, particularly with antibiotics, can improve patient outcomes. However, heterogeneity in the presentation of sepsis makes early recognition difficult, leading to increased mortality. As a result, there is an opportunity for risk assessment tools to assist clinicians in the quick and accurate identification of patients at high risk of sepsis. Many previously proposed risk assessment tools exist, including clinical approaches, laboratory tests, and sepsis-specific biomarkers; however, none are universally accepted as routine in clinical practice.

To address the need for an informative risk assessment tool in the hospital setting, we developed the Sepsis Immunoscore. The Sepsis ImmunoScore is a risk stratification tool that uses machine learning to aid in identifying patients likely to have or progress to sepsis within 24 hours of patient assessment. It was granted marketing authorization (De Novo pathway) by the United States Food and Drug Administration (FDA) in April 2024 as the first-ever Al diagnostic authorized for sepsis. The Sepsis ImmunoScore inputs up to 22 parameters derived from patient demographics, vital signs, routinely accepted general clinical laboratory tests, and sepsis specific biomarkers to generate a composite risk score. The risk score categorizes patients into one of four discrete risk groups based on the risk of sepsis. The Sepsis ImmunoScore embeds into a hospital EMR and functions as a diagnostic test, allowing healthcare providers to order and view the test results for a particular patient in the Electronic Health Record (EHR) system, similar to a laboratory test.

In this investigation, we describe the derivation and assess the performance of the Sepsis ImmunoScore functioning as a sepsis risk assessment tool. Accordingly, the objective of this investigation was to evaluate the performance of the Sepsis ImmunoScore and its ability to risk stratify patients for the presence or development of sepsis (defined by Sepsis-3) within 24 hours,

and for secondary endpoints of in-hospital mortality, hospital length of stay, ICU admission, mechanical ventilator use, and vasopressor medication use.<sup>9</sup>

### **Methods**

#### **Study Design**

We conducted a prospective, observational, multi-center study to create a sepsis artificial intelligence/machine learning (AI/ML) algorithm and assess its ability to identify the presence of sepsis within 24 hours, and other secondary outcomes of critical illness morbidity and mortality (**eFigure 1**). Participants were enrolled at one of 5 participating hospitals. We obtained study approvals from the ethics boards of participating institutions under a waiver from informed consent, except OSF Saint Francis Medical Center, which required informed consent.

## **Study Population**

Study inclusion criteria consisted of hospitalized adult patients (aged 18 or older) who had a suspected infection defined by the clinical decision to obtain a blood culture and who had a lithium-heparin (Li-Hep) plasma sample drawn within a 6-hour-window from the first blood culture order that was available for collection. There were no exclusion criteria. Subjects were enrolled between April 2017 and July 2022 from 5 hospital institution sites throughout the United States. The study participants were enrolled in three different cohorts: a *derivation cohort* (n=2,366) where the algorithm was derived, an *internal validation* cohort (n=393) that assessed algorithm performance on a second set of participants from the same hospitals used in the derivation, and a final *external validation* cohort (n=698) that used a new set of participants from hospitals not involved in the algorithm derivation (additional details in supplemental appendix).

### **Study Outcomes**

### **Endpoints**

The primary endpoint was the presence of sepsis at presentation or within 24 hours of study inclusion using the Sepsis-3 criteria: suspected infection and Sequential Organ Failure Assessment (SOFA) score of 2 or greater from baseline. The derivation cohort used a sepsis-3 outcome derived from the medical record in an automated fashion, while the internal and external validation cohorts used expert clinical adjudication to apply the definitions and determine the sepsis-3 outcome. The secondary endpoints consisted of sepsis-related metrics of critical illness including: in-hospital mortality, hospital length of stay, ICU admission, use of mechanical ventilator, and use of vasopressors.

#### **Data Collection**

Data were gathered directly through an offline EMR extraction and a transfer of de-identified data that were linked to corresponding patient blood specimens. Data elements were abstracted from the EMR and included demographic information, coded ICD-10 diagnoses, medications, vital sign measurements, clinical laboratory test results (e.g., chemistry laboratory testing results, lactic acid), and sepsis-related laboratory measurements (C-reactive protein and procalcitonin – tested at external lab – see supplemental appendix for details), secondary outcomes metrics, and relevant data to conduct adjudication (e.g., microbiology results), and relevant orders (e.g., antibiotic administration). Comorbidities were based on the components of the Charlson Comorbidity Index (CCI) and were encoded based on ICD-10-CM encodings defined by the National Cancer Institute (NCI) Comorbidity Index/SEER. Immunocompromised patients were

identified based on ICD-10-CM encodings defined by Agency for Healthcare Research and Quality (AHRQ).<sup>12,13</sup>

### **Sepsis ImmunoScore**

### **Algorithm Development**

The Sepsis ImmunoScore machine learning algorithm was created using a supervised, calibrated random forest that predicts the probability of a patient meeting Sepsis-3 criteria within 24 hours of study entry. A random forest was trained on the 2,366 patient encounters in the derivation cohort using 22 patient-specific features comprising demographics, vital signs, and laboratory tests measured close to study entry. Model parameters were optimized using 3 repeats of 5-fold-cross-validation, and missing data were imputed using bagged trees.

Predictions were calibrated to the probability of sepsis-3 to compute a sepsis risk score by regressing the outcome on the out-of-bag predictions of the random forest in the derivation cohort. Sepsis risk scores were divided into four risk stratification categories by thresholds identified during the development process using out-of-bag predictions in the derivation cohort. (See online supplement)

### Risk Score and Risk Stratification Category Generation

To assess performance, the Sepsis ImmunoScore was calculated

for patients in the internal and external validation cohorts. Calibrated out-of-bag scores were used for the derivation cohort to reduce bias from overfitting in performance estimation. No result was generated for patients lacking a measurement for PCT, CRP, white blood cell count, platelet count, creatinine, or blood urea nitrogen between 24 hours prior to study entry (blood culture order) and 3.5 hours after. Similarly, no result was generated for patients without a measurement for systolic blood pressure, diastolic blood pressure, inspired oxygen percentage,

heart rate, or respiratory rate between six hours prior to study entry and 3.5 hours after. Missing values for the remaining 12 input parameters were imputed by the Sepsis ImmunoScore to produce a sepsis risk score.

### **Statistical Analysis**

Diagnostic accuracy was assessed by determining the ability of the sepsis ImmunoScore and its corresponding risk stratification category (low, medium, high, or very high), to identify patients with the primary outcome of sepsis (sepsis-3 within 24 hours of study entry) and secondary outcomes. We estimated likelihood ratios and predictive values along with 95% confidence intervals for each of the risk categories and assessed for a monotonic increasing relationship between risk category severity and outcomes using a one-sided Cochran-Armitage hypothesis test. <sup>15,16</sup> We also estimated the area under the receiver operating characteristic curve (AUROC) of the sepsis risk score. Confidence intervals for the AUROC were estimated using a binormal approximation estimator for the standard error. <sup>17</sup> Analyses were conducted using R statistical software version 4.2.1.

#### **Sample Size Calculation**

This study was powered based on the confidence interval of the AUROC for the sepsis endpoint. The calculation assumed a sepsis prevalence of 32%, an estimated AUROC of 0.75, a maximum allowable difference between the true AUC and its estimate of 0.023, and a significance level of 0.05 resulting in an estimated sample size of 735 subjects. Additional participants were enrolled beyond these calculations to include participants of varying age, racial backgrounds, ethnicities, and geographic location. The initial study design used a single validation cohort partially enrolled from hospitals included in the derivation set; however, based on direction from the FDA, we split the cohort into the current internal and external validation format.

## **Results**

There were a total of 3,457 patient encounters included, with 2,366 encounters in the derivation set, 393 in the internal validation set, and 698 visits in the external validation set. The study enrolled participants with age, sex, race, and ethnicity, and co-morbidities typical of sepsis patients in the US (**Table 1**). The rate of sepsis was 32% in the derivation, 28% in internal validation, and 22% in the external validation cohorts (**Table 1**). Patients with sepsis had higher rates of severe illness and mortality compared to those without sepsis (**Table 1**).

#### Sepsis ImmunoScore

The Sepsis ImmunoScore algorithm uses up to 22 input parameters to generate the risk score and place patients in one of four discrete risk stratification categories. The 22 input parameters consist of demographic data (age), vital sign measurements, complete-metabolic-panel measurements, complete blood count panel measurements, lactate, and sepsis biomarkers PCT and CRP.

#### **Primary Endpoint**

The overall diagnostic accuracy for the Sepsis ImmunoScore was high for predicting sepsis with an AUC in the derivation set of 0.85 (95% confidence interval: 0.83–0.87) for the medical record derived sepsis outcome, and 0.80 (0.74–0.86) in the internal validation and 0.81 (0.77–0.86) in the external validation for the adjudicated sepsis outcome (eTable 1). The Sepsis ImmunoScore was divided into four risk categories with increasing risk of sepsis. (Figure 1, Table 2, eTable 2). Of note, in the external validation set, the likelihood ratios were: low 0.1 (0.1–0.2), medium 0.5 (0.3–0.8), high 2.1 (1.8–2.5), very high 8.3 (4.1–17.1). These are monotonically increasing and had no overlapping confidence intervals suggesting stepwise risk discrimination for sepsis.

### **Secondary Endpoints**

We assessed the prognostic ability for the Sepsis ImmunoScore to predict the secondary outcomes of ICU admission within 24 hours, in-hospital mortality, use of mechanical ventilation within 24 hours, and use of vasopressors within 24 hours. The Sepsis ImmunoScore was highly predictive of these outcomes. The Sepsis ImmunoScore categories ranging from low, medium. high, and very high demonstrated good predictive ability based on both rate of outcome as well as the corresponding stratum specific likelihood ratios (Figure 2, Table 3, eTable 3). In the external validation cohort, the observed in-hospital mortality rates in the low, medium, high, and very high risk groups were 0.0% (0.0%, 1.6%), 1.9% (0.40%–5.5%), 8.7% (5.7%–12.7%), and 18.2% (7.0%–35.5%) respectively. Additionally, the observed median number of days for the composite length of stay endpoint in the low, medium, high, and very high-risk groups were: 4.0 (3.5–4.9), 5.7 (4.9–7.0), 7.7 (6.5–8.5), and 13.5 (7.1–19.1) respectively. The proportion of patients transferred to the ICU within 24 hours was 4.7% (2.4%–8.3%), 12.7% (8.0%–19.0%), 25.7% (20.7%–31.3%), and 54.6% (36.4%–71.9%) respectively. Similar trends were observed for mechanical ventilation and vasopressor usage. Cochran-Armitage hypothesis tests indicated statistically significant monotonic increasing relationships between outcome predictive value and risk stratification category severity for each secondary endpoint (p-value < 0.01, Table 3, eTable 3). Risk stratification category severity was also associated with time to event for each secondary endpoint (eFigure 2).

## **Discussion**

The Sepsis ImmunoScore is a comprehensive, multidimensional AI/ML tool that combines demographics, vital signs, clinical laboratory tests, and sepsis focused laboratory tests to assess risk of sepsis and risk of adverse outcomes. In this study, we developed the Sepsis

ImmunoScore and aanalyzed its ability to serve as a risk-stratification tool for patients with suspected infection, and its ability to predict the diagnosis of sepsis and prognosticate adverse clinical outcomes. We found the Sepsis ImmunoScore highly predictive of sepsis and secondary outcomes of in-hospital mortality, hospital length of stay, ICU admission, mechanical ventilation, and vasopressor administration within 24 hours.

There are a number of FDA-approved diagnostic tools available for patients with an infection; however, they are typically in the form of a single blood biomarker or sometimes multiple blood biomarkers. Procalcitonin is a biomarker that evaluates the risk of progression to severe sepsis and septic shock in critically ill patients upon their first day in the ICU. 19-23 The IntelliSep Test is a blood test that measures leukocyte biophysical properties to create a score that identifies sepsis with organ dysfunction manifesting within the first three days after testing for adult patients with signs and symptoms of infection who present to the emergency department. 24-26 Another test by Beckman, the Coulter Cellular Analysis System's Early Sepsis Indicator measures Monocyte Distribution Width to identify sepsis risk.<sup>27–29</sup> Other tests distinguish bacterial from non-bacterial infection in the ED or urgent care settings such as the FebriDx test which measures myxovirus resistance protein A and CRP from finger-stick blood. 30-33 The MeMed BVTM measures blood concentrations of TRAIL, IP-10, and CRP to also distinguish patients with bacterial infections from those without.<sup>34–37</sup> The Sepsis Immunoscore has comparable or superior diagnostic accuracy to these other FDA approved tests. Moreover, the ImmunoScore uses multidimensional inputs across different domains (demographics, vital signs, laboratory tests etc.) plus sepsis biomarkers to create a comprehensive risk score for a given individual. The intent of the ImmunoScore is to embed in an EMR so that it can pull the different requisite inputs and display the score when it is ordered as a diagnostic test.

While no other AI/ML tools are FDA authorized for sepsis, many have been developed and clinically deployed, especially early detection tools that passively monitor patient data and alert clinicians when sepsis is suspected. The reported performance of these tools varies widely,

and recent validation studies have raised concerns about their use.<sup>38–41</sup> A large, external validation study of the widely deployed Epic Sepsis Model in 2021 reported an AUC of only 0.63,<sup>38</sup> and recent reviews of validation studies of the Targeted Real-time Early Warning System (TREWS) score have raised concerns regarding the control group and false positives.<sup>39</sup> Concerns of alert fatigue have also been raised for these systems, which may undermine their clinical utility.<sup>42–44</sup>

The application of Al/ML to medicine has great potential, much of which is underdeveloped in medicine. The Sepsis ImmunoScore used clinically available data reflective of patient biologic state and machine learning to incorporate and identify objective patient assessments that are causally related to sepsis and associated adverse outcomes. Input features were carefully curated to select for measures of patient biology and pathophysiology that underlie critical illness and are routinely collected or available in the setting of infection. We did not include as eligible covariates subjective determinations or interventions that could be heavily influenced by site-specific protocols, clinician-specific perspectives, or other peculiarities of care. In addition to accurately diagnosing sepsis in an external validation set, we attribute the simultaneous association of the Sepsis ImmunoScore with other adverse outcomes in part to an explicit focus on patient host response biology. The result of this careful synthesis is a diagnostic tool that capitalizes on the synergy of thoughtfully applied Al/ML to expertly curated biologic data to better equip—not replace—clinicians in their challenging fight against sepsis.

Sepsis represents an ongoing diagnostic challenge to clinicians due to its often subtle and heterogeneous presentation. Determining the presence or likelihood of progression to sepsis, and the severity with associated clinical needs represents a continuing challenge to clinicians. The Sepsis ImmunoScore is unique in its approach due to its machine-learning based incorporation of 22 parameters to comprehensively assess a patient's risk of being diagnosed with sepsis, plus its association with adverse outcomes. The ImmunoScore should serve as an adjunctive test to assist clinical decision making in the acute setting. Given its

strong predictive ability, the Sepsis ImmunoScore may help to improve patient outcomes by adequately informing physician decisions for patients potentially requiring sepsis-related care, such as the rapid administration of broad-spectrum antimicrobials, escalation of care, and administration of fluid or vasopressor medications. It may also help to reduce over-triage by more accurately identifying patients at low risk for deterioration due to infection, for example allowing emergency department physicians to potentially treat these low -isk patients in the outpatient setting and promote antimicrobial stewardship.

#### **Limitations**

There are a number of limitations to our study. First, we used 5 hospitals in the study, it is possible that our findings may not generalize to specific populations that may differ from our hospitals. Second, we relied upon an EMR extraction, so it is possible that missingness or the use of ICD10 codes may have led to misclassification of certain elements such as comorbidities. Third, this was an observational study so we cannot assess the impact of the ImmunoScore on clinical decision-making and changes in therapeutic approaches. Fourth, the primary outcome of Sepsis-3 within 24 hours relied upon an automated calculation in the derivation set and adjudication for presence of infection in the internal and external validation; thus, misclassification of outcome may have occurred. Fifth, our inclusion criteria used the ordering of a blood culture as a surrogate indicator for a clinical suspicion of infection and patients where there was a clinical suspicion may not have had a blood culture ordered or other patients may have had a blood culture performed who had a very low (or no) suspicion of infection. Finally, covariate missingness may have affected algorithm performance.

# **Conclusions**

The Sepsis ImmunoScore has demonstrated robust risk assessment performance in derivation, internal, and external validation. Future work is warranted to further establish its generalizability to other settings. Finally, additional studies are warranted to assess the impact of the Sepsis ImmunoScore on clinical decision-making, sepsis care, and associated resource utilization and costs. These investigations are ongoing.

## **Acknowledgements**

**Authorship Contributions:** Dr. Shapiro and Bhargava had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Bhargava, Lopez-Espina, Schmalz, Watson, Zhao, Zhu, Bashir, and Reddy Jr., and Shapiro

Acquisition, analysis, and interpretation of data: Bhargava, Lopez-Espina, Schmalz, Khan, Urdiales, Updike, Kurtzman, Dagan, Doodlesack, Stenson, Sarma, Reseland, Lee, Kravitz, Antkowiak, Shvilkina, Espinosa, Halalau, Demarco, Davila, Davila, Sims, Maddens, Berghea, Smith, Palagiri, Ezekiel, Sadaka, Iyer, Crisp, Azad, Oke, Friederich, Syed, Gosai, Chawla, Evans, Thomas, Malkani, Patel, Mayer, Ali, Raghavakurup, Tafa, Singh, and Raouf

Drafting of the manuscript: Bhargava, Watson, and Shapiro

Critical revision of the manuscript for important intellectual content. All authors

Statistical analysis: Bhargava, Schmalz, and Watson

Obtained funding: Lopez-Espina, Watson, Bashir, and Reddy Jr.

Administrative, technical, or material support: Reddy Jr.

Study supervision: Bhargava, Lopez-Espina, Schmalz, Reddy Jr., and Shapiro

**Funding/Support:** This study was funded in part by the Defense Threat Reduction Agency, National Institutes of Health, Centers for Disease Control and Prevention, National Science Foundation, Biomedical Advanced Research and Development Authority, and Prenosis.

**Role of the Funder/Sponsor:** Prenosis was overall responsible for the design and conduct of the study, collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The other funding agencies had no role.

Conflict of Interest Disclosures: Zhao, Zhu, Shapiro and Bashir are consultants to Prenosis. Bhargava, Lopez-Espina, Schmalz, Khan, Watson, Uridales, Updike, and Reddy. Jr are employed by Prenosis. Bashir and Shapiro have equity ownership in Prenosis, and Bashir has equity interest in VedaBio. Dr. Shapiro is a consultant for Luminos technologies, Cambridge Medical Technologies, and receives research support from Bluejay diagnostics and Inflammatix.

**Acknowledgement Statement:** We are indebted to the study coordinators, research staff, and lab technicians who participated in the study. These contributions were part of these individuals' jobs, and they did not receive additional compensation.

## References

- Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *The Lancet*. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7
- Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. *Crit Care Med.* 2014;42(8):1749-1755. doi:10.1097/CCM.0000000000000330
- Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. *Crit Care Med.* 2010;38(4):1045-1053. doi:10.1097/CCM.0b013e3181cc4824
- Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med.* 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9
- Puskarich MA, Trzeciak S, Shapiro NI, et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. *Crit Care Med.* 2011;39(9):2066-2071. doi:10.1097/CCM.0b013e31821e87ab
- Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical care medicine. 2021;49(11):e1063e1143.
- 7. Liu VX, Fielding-Singh V, Greene JD, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. *Am J Respir Crit Care Med.* 2017;196(7):856-863. doi:10.1164/rccm.201609-1848OC
- 8. Filbin MR, Lynch J, Gillingham TD, et al. Presenting symptoms independently predict mortality in septic shock: importance of a previously unmeasured confounder. *Critical care medicine*. 2018;46(10):1592-1599.
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801. doi:10.1001/jama.2016.0287
- 10. Centers for Disease Control and Prevention. Hospital Toolkit for Adult Sepsis Surveillance. Published online 2018.
- 11. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. *Jama*. 2017;318(13):1241-1249.
- 12. National Cancer Institute. SEER-Medicare: Considerations Comorbidity Table. Accessed March 27, 2024.
  - https://healthcaredeliverv.cancer.gov/seermedicare/considerations/comorbidity-table.html

- 13. Agency for Healthcare Research and Quality. Prevention Quality Indicators Appendix C. Accessed August 30, 2023. <a href="https://qualityindicators.ahrq.gov/Downloads/Modules/PQI/V60-ICD10/TechSpecs/PQI">https://qualityindicators.ahrq.gov/Downloads/Modules/PQI/V60-ICD10/TechSpecs/PQI</a> Appendix C.pdf
- 14. Platt J. Probabilistic outputs for support vector machines and comparisons to regularized likelihood methods. *Advances in large margin classifiers*. 1999;10(3):61-74.
- 15. Cochran WG. Some methods for strengthening the common  $\chi$  2 tests. *Biometrics*. 1954;10(4):417-451.
- 16. Armitage P. Tests for linear trends in proportions and frequencies. *Biometrics*. 1955;11(3):375-386.
- 17. Obuchowski NA. Sample size calculations in studies of test accuracy. *Statistical Methods in Medical Research*. 1998;7(4):371-392.
- 18. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. *The Lancet*. 2005;365(9469):1500-1505.
- U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Substantial Equivalence Determination Decision Summary, Roche Diagnostics K173927. Accessed April 17, 2024. <a href="https://www.accessdata.fda.gov/cdrh\_docs/reviews/K173927.pdf">https://www.accessdata.fda.gov/cdrh\_docs/reviews/K173927.pdf</a>
- 20. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *The Lancet*. 2010;375(9713):463-474.
- Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *American journal of* respiratory and critical care medicine. 2008;177(5):498-505.
- 22. Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. *Critical care*. 2009;13:1-7.
- 23. Karlsson S, Heikkinen M, Pettilä V, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. *Critical Care*. 2010;14:1-10.
- 24. O'Neal Jr HR, Sheybani R, Janz DR, et al. Validation of a Novel, Rapid Sepsis Diagnostic for Emergency Department Use. *Critical Care Explorations*. 2024;6(2):e1026.
- U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Substantial Equivalence Determination Decision Summary, Cytovale Inc. K220991. Accessed April 17, 2024. <a href="https://www.accessdata.fda.gov/cdrh\_docs/reviews/K220991.pdf">https://www.accessdata.fda.gov/cdrh\_docs/reviews/K220991.pdf</a>
- 26. Guillou L, Sheybani R, Jensen AE, et al. Development and validation of a cellular host response test as an early diagnostic for sepsis. *PLoS One*. 2021;16(4):e0246980.
- 27. Crouser ED, Parrillo JE, Seymour CW, et al. Monocyte distribution width: a novel indicator of sepsis-2 and sepsis-3 in high-risk emergency department patients. *Critical care medicine*. 2019;47(8):1018-1025.

- 28. Jo SJ, Kim SW, Choi JH, Choi SP, Lee J, Lim J. Monocyte distribution width (MDW) as a useful indicator for early screening of sepsis and discriminating false positive blood cultures. *Plos one*. 2022;17(12):e0279374.
- 29. U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Substantial Equivalence Determination Decision Summary, Beckman Coulter, Inc K181599. Accessed April 18, 2024. https://www.accessdata.fda.gov/cdrh\_docs/reviews/K181599.pdf
- U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Substantial Equivalence Determination Decision Summary, FebriDx K230917. Accessed April 18, 2024. https://www.accessdata.fda.gov/cdrh\_docs/reviews/K230917.pdf
- 31. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. *Annals of medicine*. 2018;50(5):420-429.
- 32. Tong-Minh K, Daenen K, Endeman H, et al. Performance of the FebriDx Rapid Point-of-Care Test for Differentiating Bacterial and Viral Respiratory Tract Infections in Patients with a Suspected Respiratory Tract Infection in the Emergency Department. *Journal of Clinical Medicine*. 2023;13(1):163.
- 33. Shirley M. FebriDx®: a rapid diagnostic test for differentiating bacterial and viral aetiologies in acute respiratory infections. *Molecular diagnosis & therapy*. 2019;23(6):803-809.
- U.S. Food and Drug Administration, Center for Devices and Radiological Health. 510(k) Substantial Equivalence Determination Decision Summary, MeMed Diagnostics Ltd. K210254. Accessed April 18, 2024. https://www.accessdata.fda.gov/cdrh\_docs/reviews/K210254.pdf
- 35. Oved K, Cohen A, Boico O, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. *PloS one*. 2015;10(3):e0120012.
- 36. Srugo I, Klein A, Stein M, et al. Validation of a novel assay to distinguish bacterial and viral infections. *Pediatrics*. 2017;140(4).
- 37. Papan C, Argentiero A, Porwoll M, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study. *Clinical Microbiology and Infection*. 2022;28(5):723-730.
- 38. Wong A, Otles E, Donnelly JP, et al. External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients. *JAMA Internal Medicine*. 2021;181(8):1065-1070. doi:10.1001/jamainternmed.2021.2626
- 39. Schinkel M, van der Poll T, Wiersinga WJ. Artificial intelligence for early sepsis detection: a word of caution. *American journal of respiratory and critical care medicine*. 2023;207(7):853-854.

- 40. Fleuren LM, Klausch TL, Zwager CL, et al. Machine learning for the prediction of sepsis: a systematic review and meta-analysis of diagnostic test accuracy. *Intensive care medicine*. 2020;46:383-400.
- 41. Patton MJ, Liu VX, Might M. Temporal analysis of biomarker, severity-of-illness score, and machine learning model performance for sepsis prediction. In: 42nd International Symposium on Intensive Care & Emergency Medicine, ISICEM 2023; 2023.
- 42. Medicine TLR. Crying wolf: the growing fatigue around sepsis alerts. *The Lancet Respiratory Medicine*. 2018;6(3):161. doi:10.1016/S2213-2600(18)30072-9
- 43. Makam AN, Nguyen OK, Auerbach AD. Diagnostic accuracy and effectiveness of automated electronic sepsis alert systems: a systematic review. *Journal of hospital medicine*. 2015;10(6):396-402.
- 44. Hwang MI, Bond WF, Powell ES. Sepsis alerts in emergency departments: a systematic review of accuracy and quality measure impact. *Western Journal of Emergency Medicine*. 2020;21(5):1201.
- 45. Maslove DM, Tang B, Shankar-Hari M, et al. Redefining critical illness. *Nature medicine*. 2022;28(6):1141-1148.

## **Figure Legends**

**Figure 1. Sepsis ImmunoScore Stratification for Sepsis-3 in all Cohorts.** Barplots are shown for the derivation, internal validation, and external validation datasets for the Sepsis-3 within 24 hours PVs for each Sepsis ImmunoScore risk stratification category. Dashed lines indicate the 95% CIs.

**Figure 2. Sepsis ImmunoScore Risk Stratification for Morbidity and Mortality (External Validation).** Barplots are shown for the derivation, internal validation, and external validation datasets for the secondary endpoints PVs (ICU transfer within 24 hours, in-hospital mortality, mechanical ventilation within 24 Hours, vasopressor administration within 24 Hours, and length of stay from inclusion time) for each Sepsis ImmunoScore risk stratification category. Dashed lines indicate the 95% CIs.

# **Tables**

Table 1. Baseline Data and Adverse Outcomes for Derivation, Internal Validation and External Validation

	Patients Encounters, No. (%)				
Characteristic	Derivation	Internal Validation	External Validation		
	(N = 2366)	(N = 393)	(N = 698)		
Clinical Site	-				
Beth Israel Deaconess Medical Center – Boston, MA	0 (0.0)	0 (0.0)	356 (51.0)		
OSF – Peoria, IL	712 (30.1)	87 (22.1)	0 (0.0)		
Jesse Brown VA - Chicago, IL	0 (0.0)	0 (0.0)	65 (9.3)		
Mercy Health - St. Louis, MO	1061 (44.8)	306 (77.9)	0 (0.0)		
Beaumont - Royal Oak, MI	0 (0.0)	0 (0.0)	277 (39.7)		
Carle Foundation Hospital – Urbana, IL	593 (25.1)	0 (0.0)	0 (0.0)		
Age (mean (SD))	64.20 (16.59)	64.06 (17.66)	62.80 (17.01)		
Male (%)	1195 (50.5)	210 (53.4)	391 (56.0)		
Race					
American Indian or Alaska Native	1 (0.0)	0 (0.0)	2 (0.3)		
Asian	12 (0.5)	2 (0.5)	14 (2.0)		
Black or African American	315 (13.3)	57 (14.5)	154 (22.1)		
Native Hawaiian or Other Pacific Islander	0 (0.0)	0 (0.0)	1 (0.1)		
Unknown	85 (3.6)	12 (3.1)	119 (17.0)		
White	1953 (82.5)	322 (81.9)	408 (58.5)		
Ethnicity					
Hispanic or Latino	26 (1.1)	2 (0.5)	96 (13.8)		
Not Hispanic or Latino	1725 (72.9)	385 (98.0)	564 (80.8)		
Unknown	615 (26.0)	6 (1.5)	38 (5.4)		
High-Risk Comorbidities					
Acute Myocardial Infarction (%)	97 (4.1)	11 (2.8)	43 (6.2)		
History of Myocardial Infarction (%)	101 (4.3)	21 (5.3)	54 (7.7)		
Congestive Heart Failure (%)	583 (24.6)	103 (26.2)	170 (24.4)		
Peripheral Vascular Disease (%)	225 (9.5)	49 (12.5)	72 (10.3)		
Cerebrovascular Disease (%)	130 (5.5)	38 (9.7)	65 (9.3)		
Chronic Obstructive Pulmonary Disease (%)	606 (25.6)	107 (27.2)	171 (24.5)		
Dementia (%)	167 (7.1)	45 (11.5)	72 (10.3)		
Paralysis (%)	68 (2.9)	10 (2.5)	20 (2.9)		
Diabetes (%)	630 (26.6)	101 (25.7)	156 (22.3)		

Diabetes with Complications (%)	423 (17.9)	93 (23.7)	155 (22.2)
Renal Disease (%)	659 (27.9)	123 (31.3)	216 (30.9)
Mild Liver Disease (%)	118 (5.0)	19 (4.8)	94 (13.5)
Moderate and Severe Liver Disease (%)	45 (1.9)	6 (1.5)	55 (7.9)
Peptic Ulcer Disease (%)	45 (1.9)	8 (2.0)	13 (1.9)
Rheumatologic Disease (%)	105 (4.4)	17 (4.3)	33 (4.7)
AIDS (%)	17 (0.7)	2 (0.5)	6 (0.9)
Immunocompromised (%)	470 (19.9)	117 (29.8)	190 (27.2)
COVID-19 (%)	189 (8.0)	28 (7.1)	73 (10.5)
Adverse Outcomes			
Sepsis-3 within 24 hours (%)	763 (32.2)	108 (27.5)	151 (21.6)
In-hospital Mortality (%)	147 (6.2)	33 (8.4)	33 (4.7)
ICU Transfer (%)	491 (27.7)	144 (36.6)	151 (21.6)
Placement of Mechanical Ventilation (%)	191 (8.1)	44 (11.2)	51 (7.3)
Administration of Vasopressors (%)	223 (9.4)	53 (13.5)	77 (11.0)
Length of Stay (median [IQR])	4.7 [2.6, 8.5]	4.98 [2.8, 10.8]	5.94 [3.3, 10.4]

Table 2. Sepsis ImmunoScore Risk Stratification for Sepsis-3 Within 24 Hours

Cohort	ImmunoScore Risk Category	Total Patients	Septic Patients	Sepsis PV [95% CI]	Sepsis Likelihood Ratio [95% CI]	Cochran- Armitage Test (p- value)
External	Low	232	7	3.0% [1.2%, 6.1%]	0.1 [0.1, 0.2]	< 0.001
Validatio n	Medium	157	20	12.7% [7.96%, 19.0%]	0.5 [0.3, 0.8]	
(N = 698)	High	276	101	36.6% [30.1%, 42.6%]	2.1 [1.8, 2.5]	
	Very High	33	23	69.7% [51.3%, 84.4%]	8.3 [4.1, 17.1]	

Table 3. External Validation Immuno Score Risk Stratification for Morbidity and Mortality

Secondary Outcome	Sepsis Risk Category	Total Patients	Patients with Event	Predictive Value [95% CI]	Likelihood Ratio [95% CI]	Days [95% CI]	Cochran- Armitage Test (p-value)
	Low	232	11	4.7% [2.4%, 8.3%]	0.2 [0.1, 0.4]	-	< 0.001
ICU Transfer	Medium	157	20	12.7% [8.0%, 19.0%]	0.7 [0.4, 1.1]	-	
within 24 Hours	High	276	71	25.7% [20.7%, 31.3%]	1.7 [1.3, 2.1]	-	
	Very High	33	18	54.6% [36.4%, 71.9%]	5.8 [3.0, 11.3]	-	
In-Hospital Mortality	Low	232	0	0.0% [0.0%, 1.6%]	0.0 [0.0, -]	-	< 0.001
	Medium	157	3	1.9% [0.4%, 5.5%]	0.4 [0.1, 1.2]	-	
	High	276	24	8.7% [5.7%, 12.7%]	1.9 [1.3, 2.9]	-	
	Very High	33	6	18.2% [7.0%, 35.5%]	4.5 [1.9, 10.7]	-	

Mechanical Ventilation within 24 Hours	Low	232	6	2.6% [1.0%, 5.5%]	0.5 [0.2, 1.2]	-	0.008
	Medium	157	6	3.8% [1.4%, 8.1%]	0.8 [0.4, 1.8]	-	
	High	276	18	6.5% [3.9%, 10.1%]	1.4 [0.9, 2.2]	-	
	Very High	33	3	9.1% [1.9%, 24.3%]	2.0 [0.6, 6.6]	-	
Vasopressor within 24 Hours	Low	232	2	0.9% [0.1%, 3.1%]	0.1 [0.0, 0.5]	-	< 0.001
	Medium	157	3	1.9% [0.4%, 5.5%]	0.3 [0.1, 0.8]	-	
	High	276	32	11.6% [8.1%, 16.0%]	1.7 [1.2, 2.4]	-	
	Very High	33	13	39.4% [22.9%, 57.9%]	8.4 [4.2, 16.7]	-	
Length of Stay	Low	232	232	-	-	4.0 [3.5, 4.9]	
	Medium	157	157	-	-	5.7 [4.9, 7.0]	
	High	276	276	-	-	7.7 [6.5, 8.5]	
	Very High	33	33	-	-	13.5 [7.1, 19.1]	



